Inv(11)(q21q23) fuses MLL to the Notch co-activator mastermind-like 2 in secondary T-cell acute lymphoblastic leukemia The human MLL gene is frequently involved in genetic rearrangements, all of which associated with malignancies of the hematopoietic system. More than 50 rearrangements have so far been characterized at the molecular level; however, only a small portion of these MLL fusions can be recurrently identified in therapy-related malignancies. Secondary leukemias usually present as myelodysplastic syndrome or therapy-related acute myeloid leukemia (t-AML) and are characterized by the localization of the genomic breakpoint in a subregion of the MLL breakpoint cluster region, associated with specific sequence features indicating that topoisomerase II inhibition by etoposide treatment may be involved in t-AML induction. 1 Genetic rearrangements of MAML2 have first been described for a subset of salivary gland tumors. 2 Fusions between MLL and MAML2 have recently been reported for two adult leukemia patients with secondary AML and myelodysplastic syndrome. 3 Here, we describe the development of secondary T-cell acute lymphoblastic leukemia (T-ALL) in two adolescent leukemia patients. Therapy-related ALL (t-ALL) was diagnosed in a 13-year-old boy 20 months after cessation of treatment for primary AML FAB-M4 Eo. The karyotype of primary AML was 46,XY,inv(16)(p13q22),del(7)(q22), þ 8. The patient had been treated according to the standard risk group arm of the AML-BFM 98 study with high-dose cytarabine, etoposide, idarubicine and mitoxantrone. At presentation of t-ALL, he had severe breathing difficulties because of a large mediastinal mass. Surface marker expression classified the t-ALL as cortical T-cell lineage ALL with co-expression of the myeloid marker CD13, and the progenitor marker CD117. An MLL rearrangement (46,XY,inv(11)(q21q23) [20] . nuc ish 9q21 (P16x2), 11q23 (MLL prox Â 2; MLL dist Â 2)(MLL prox sept MLL dist Â 1)) with an unknown fusion partner was identified by dual-color fluorescence in situ hybridization (FISH). The patient achieved remission on the high-risk arm of the ALL-BFM 2000 study, received a hematopoietic stem cell transplant from an unrelated donor and is without evidence of disease 4 years post transplantation.
The second patient, an 11-year-old girl, presented with dacryocystitis and enlarged lymph nodes 5 years after initial diagnosis of B-cell precursor (BCP)-ALL. Flowcytometric analysis of the primary ALL showed common ALL phenotype with aberrant expression of CD66c, the myeloid marker CD13 and the progenitor marker CD117. The bone marrow karyotype was 47,XX, þ 8 [2] /46,XX [18] . FISH analysis confirmed the cyto genetic findings and trisomy of chromosome 8 on 82% of cells in the interphase analysis. Treatment according to the standard risk arm of the ALL-BFM 95 protocol led to complete remission. Three years after initial diagnosis and 11 months after the end of maintenance therapy, a late combined ALL relapse of bone marrow and central nervous system was diagnosed. Morphological remission was induced by treatment according to the ALL-REZ BFM 96 protocol. After the fourth course with VP-16, the patient suffered a third episode of acute leukemia presenting with bone marrow and cornea infiltration, which showed cortical T-cell ALL phenotype. The karyotype was 46,XX,i(7) (q10),inv(11)(q21q23) [ The underlying genetic lesions were first investigated for both patients by interphase split-signal FISH (shown for case 1 in Figure 1a ) and confirmed by Southern blot (Figure 1b) . Religated BamHI DNA fragments were amplified by long-distance inverse PCR 4 and sequence analyses of both aberrant PCR products revealed two independent recombination events of MLL and MAML2 at 11q21 (Figure 1c ). Breakpoint positions in MLL intron 11 were nucleotides 6588/6591 in case 1 and nucleotides 6322/6319 in case 2 (according to GenBank reference sequence U04737). In MAML2, genomic breaks were located in intron 3 (nucleotides 47350/47353) in case 1 and intron 2 (nucleotides 72791/72783) in case 2 (according to GenBank reference sequence AP000779). The breakpoint position in case 1 at nucleotides 6588/6591 of the MLL BCR, in particular, is a recombination hotspot in t-AML and colocalizes precisely with the region experimentally shown to be affected by double-strand breaks after incubation with topoisomerase II inhibitors. 5 This site is also close to a DNase I hypersensitivity site, where MLL cleavage can be generated in response to apoptotic triggers. Specifically designed FISH probes confirmed the MAML2 disruption on interphase nuclei of the patient's leukemic blasts (Figure 1d ). Opposite transcriptional orientation of MLL ( þ strand) and MAML2 (À strand) allows correct recombination of exons on either fusion site after inversion (Figures 1e and f) . Fusion transcripts were amplified for both the MLL-MAML2 and reciprocal MAML2-MLL chimeric mRNA by reverse transcription PCR ( Figure 1g ) and showed in-frame fusion of MLL exon 11 to MAML2 exon 3 (in case 1) and MAML2 exon 2 (in case 2). Accordingly, in the reciprocal transcript, MAML2 exon 2 and MAML2 exon 1, respectively, were fused to MLL exon 12. An alternatively spliced variant of the MLL-MAML2 transcript lacking exon 11 was also detected in both patients. The genomic organization of the fusion genes and the chimeric fusion protein resulting from inversion inv(11)(q21q23) are depicted (Figure 1h) .
In an attempt to backtrack these patient-specific fusions, the identified genomic break points were used for nested PCR and real-time quantitative PCR experiments to identify the first appearance of pre-leukemic cells with 11q inversion and to assess minimal residual disease levels after initiation of treatment. In case 1, the genomic fusion resulting from inv(11)(q21q23) was not detectable at primary diagnosis of AML, but turned positive 4 weeks before the clinical diagnosis of secondary ALL; after ALL induction therapy, the inversion positive clone was no longer detectable ( Figure 2a) . The latency between primary AML and t-ALL was 38 months, which falls within the range (9-48 months; median 19 months) reported in other patients of MLL-positive t-ALL. In case 2, MAML2-MLL rearranged cells were detectable 5 years after initial ALL and 2 years after diagnosis of the first relapse (Figure 2b ). Retrospectively, the inversion was already present in a considerably Clinical course and fusion gene detection. Time course of clinical diagnosis, treatment and samples analyzed by molecular markers is shown for case 1 (a) and case 2 (b). (a) Diagnosis of primary AML, secondary T-ALL, stem cell transplantation (SCT) and duration of the respective therapy protocols refer to the time scale below. The chromosomal inversion was already detectable four weeks before clinical diagnosis of the secondary ALL. After SCT, no residual cells with inv(11)(q21q23) could be detected. Germline MLL amplification was performed to check DNA integrity. M, length marker; N, negative control; W, non-template control. The initial AML clone expressing the CBF-MYH11 fusion transcript (as result of inv(16)(p13q22)) was efficiently eradicated by initial chemotherapy. Absence of IG/TCR rearrangements specific for the secondary T-ALL (for example, Vg8/ Jg2.3; Vg2/Jg2-3; DH7.27/JH4b) in AML samples from initial diagnosis and during treatment further supports the classification as therapyrelated secondary disease. (b) In case 2, therapy response and growth dynamics of primary BCP-ALL, relapse, and secondary T-ALL blasts were quantified by real-time quantitative PCR using the genomic MAML2-MLL fusion site and Ig/TCR rearrangements as clonal markers. AML, acute myeloid leukemia; T-ALL, T-cell acute lymphoblastic leukemia; BCP, B-cell precursor.
Figure 3
Target gene expression in MLL-MAML2-positive T-ALL cells. Expression profiles in patient's leukemic cells were compared to four additional pediatric T-ALL patients and previously published data sets. Analyses are based on differentially expressed genes between cortical T-ALL with MLL-MAML2 fusion (case 1 and 2) and primary cortical T-ALL controls (cT-ALL 1-4) without inv(11)(q21q23). (a) Principal component analysis of cases 1 and 2, four additional primary T-ALL patients and previously reported expression data 7 in pediatric patients with B-MLL (n ¼ 20), T-ALL (n ¼ 14) or T-MLL (n ¼ 5), respectively. Control patients processed in this study (cT-ALL 1-4) cluster according to their immunophenotypic and genetic subtype correctly within the respective group. In contrast, cases 1 and 2 are projected close to each other in similar distance to the T-ALL and T-MLL cluster. (b) Discriminating genes with P-value o0.01 were used for two-dimensional cluster analysis. The presence or absence of MLL rearrangement and activating NOTCH1 mutation status is indicated by þ or À, respectively. (c) Expression of typical downstream genes of the NOTCH pathway and MLL target genes was compared between case 1, case 2, control patients with cortical T-ALL (black bars) and previously published patients (open circles). T-ALL, T-cell acute lymphoblastic leukemia.
primary disease (with a sensitivity of 10 À5 cells) further corroborate the characterization as secondary malignant neoplasm.
MAML2 belongs to MAML family, all of which localize to nuclear bodies, share a conserved basic domain in their N termini that binds to intracellular NOTCH, and contain a C-terminal transcription activation domain. NOTCH-ICN forms a multiprotein activator complex on NOTCH target genes. The activator complex is composed of the transcription factors CLS, MAML protein, DELTEX and nuclear co-activators to induce downstream target genes (for example, HES genes, p21, CD25 and so on). MAML2 acts as a transcriptional co-activator for NOTCH proteins and is widely expressed in high levels in placenta, salivary gland and skeletal muscle. Given the crucial role of the NOTCH pathway in self-renewal potential of hematopoietic stem cells and T-cell commitment, 6 we hypothesized that aberrant NOTCH signaling is mediated by the MLL-MAML2 fusion protein that might initiate T-cell leukemia development. To test this hypothesis, we analyzed cases 1 and 2 in comparison to four pediatric primary cortical T-ALL patients and previously published data sets on the Affymetrix Human Genome U133A microarray.
In a principal component analysis, cases 1 and 2 are projected close to each other in similar distance to the T-ALL, T-MLL and B-MLL cluster from the data sets of Ross et al. 7 Control patients (cT-ALL 1-4) processed in this study along with cases 1 and 2 cluster according to their immunophenotypic and genetic subtype correctly within the respective group (cortical T-ALL children without MLL aberration (cT-ALL 1-3) cluster with T-ALL patients, cortical T-ALL patient 4 (cT-ALL 4) with MLL-ENL fusion clusters with T-MLL patients (4 Â MLL-ENL, 1 Â unknown partner gene; Figure 3a) .
Of 7986 probe sets left after filtering for absent or low-level hybridization, 101 genes were found differentially expressed (t-test, Po0.01) in MLL-MAML2-positive patients 1 and 2 vs cortical T-ALL control samples without chromosomal aberration (cT-ALL 1-3) or MLL-ENL fusion (cT-ALL 4; Figure 3b and Supplementary Information). Interpretation of the microarray profiling has to be more descriptive owing to limited options for comprehensive statistical analysisFin particular, correction for multiple testingFwith only two patients representing the MLL-MAML2 group.
However, among these 101 differentially expressed genes, the number of represented genes and direction of regulation suggest the involvement of apoptosis resistance and the activation of Notch downstream genes in MLL-MAML2-positive blasts. The highest upregulation between the MLL-MAML2-positive and control patients was observed for ID1. Generally, ID proteins have been implicated in the control of differentiation and transcriptional modulation of cell-cycle regulators, and high levels of ID1 expression are frequently detected in various cancer types. Most recently, ID1 protein was identified as a key transcriptional regulator of HSC lineage commitment and functional factor of self-renewal in adult tissue stem cells. 8 Aberrant ID1-mediated maintenance of self-renewal capacity might therefore provide another mechanism of leukemic transformation initiated by the MLL-MAML2 fusion.
The antiapoptotic genes MCL1 (myeloid cell leukemia 1), BAG3 (BCL2-associated athanogene 3) and CFLAR (CASP8 and FADD-like apoptosis regulator (FLIP)) showed marked upregulation, whereas the proapoptotic genes FASTK (Fas-activated serine/threonine kinase) and PDCD6 (programmed cell death 6) were downregulated.
Significant upregulation of homeobox genes, in particular HOXA9, HOXA10 and MEIS1, previously classified as a hallmark for MLL-rearranged ALL independent of phenotypic differentiation, was not detectable in either of the two patients. HOXA5 was overexpressed exclusively in control cT-ALL 4 (MLL-ENL-positive), whereas both patients expressing the MLL-MAML2 fusion proteins showed expression levels within the range of MLL-negative patients (Figure 3c ). The presence of constitutively activating NOTCH1 mutations in control patients cT-ALL1, 3 and 4 did not significantly alter the expression of the NOTCH target genes PTCRA and ID1 (Figure 3c) .
The exact molecular mechanisms are still unclear and secondary mutations acquired after the initial translocation event may influence the final tumor phenotype. However, in analogy to other translocation partners with nuclear localization and transcription factor activity, such as ENL, ELL, AF10 and AFX, it appears likely that acquisition of the MAML2 transcription activation domain by the chimeric fusion protein acts as critical component in MLL-MAML2-mediated leukemogenesis.
In conclusion, the repertoire of MLL-mediated leukemias has been extended by another gene that is involved in NOTCH signaling important for stem cells and lymphocytic development. This balanced MLL fusion has been identified, as a treatment-related event in two independent leukemia patients demonstrating the MLL-MAML2 fusions may be a recurrent event. Thus, the established probes for split-signal FISH and reverse transcription PCR may be of value for those who were facing secondary T-ALL after treatment.
